Wedbush raised the firm’s price target on Praxis Precision (PRAX) to $130 from $95 and keeps an Underperform rating on the shares. The firm says that most notable in the Q4 2025 update, management completed NDA submissions for both ulixacaltamide in ET and relutrigine in SCN2A/SCN8A DEE. NDA acceptance likely arrives mid-April, while management requested priority review solely for relutrigine – not ulixacaltamide. Bottom line, Wedbush continues to hold reservations on the ulixacaltamide filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $412 from $357 at Deutsche Bank
- Praxis Precision price target raised to $433 from $275 at Baird
- Praxis Precision price target raised to $305 from $282 at Wells Fargo
- Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline Toward Commercialization with Multibillion-Dollar Market Potential
- Praxis Precision Medicines: NDA Progress, Robust Pipeline, and Strong Cash Runway Support Buy Rating